Health Care Select Sector SPDR Fund : XLV

XLV

Stock Data

$159.49

$1.60 (0.99%)

Asset Type

N/A

Exchange

N/A

Currency

N/A

Country

N/A

Sector

N/A

Industry

N/A

All XLV Articles

23 Articles

David Beren | Jul 9, 2026 at 12:18 PM EDT

Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%

The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is the default healthcare allocation for millions of investors, and for good…

Omor Ibne Ehsan | Jul 7, 2026 at 2:45 PM EDT

Goldman’s Top Strategist Sees a Dangerous Amount of Leverage Piling Up

Ben Snider, Chief U.S. Equity Strategist at Goldman Sachs, went on CNBC to say something that should register with anyone…

Marc Guberti | Jun 21, 2026 at 4:17 PM EDT

The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026

The Health Care Select Sector SPDR ETF (NYSEARCA:XLV) is having a frustrating year. The fund sits at $149, down about…

Joel South | Jun 13, 2026 at 9:30 AM EDT

3 Ridiculously Cheap Healthcare Stocks to Buy in June

Healthcare has spent 2026 on the sidelines while the rest of the market does the heavy lifting. The Health Care…

Thomas Richmond | Jun 7, 2026 at 9:30 AM EDT

Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech

After years of lagging the market, healthcare may be taking on a new role in investor portfolios. Speaking on CNBC,…

David Moadel | Jun 4, 2026 at 1:32 PM EDT

Humana Jumps 6%, UnitedHealth Climbs 5%, Cigna Rises 4% as Analysts Cheer Softer Medical Cost Trends

Health insurers are running higher in Thursday afternoon trading after a wave of bullish Wall Street analyst notes on the…

Tony Dong | May 20, 2026 at 8:30 AM EDT

When 2022 Tore Through the S&P 500, This Healthcare ETF Barely Flinched. Why Isn’t It in More Retirement Accounts?

2022 was a really weird year to be an investor. Even four years later, I still remember what happened. A…

Omor Ibne Ehsan | May 19, 2026 at 4:19 PM EDT

Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

The iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is the rare fund that has spent the past year being publicly threatened by…

Austin Smith | Apr 29, 2026 at 7:23 AM EDT

Healthcare’s Defensive Promise Crumbles: XLV Down 7% While SPY Rises 5% in 2026

Healthcare is supposed to be the place you hide. It is the fourth-largest slice of U.S. GDP at 8.9% in…

Michael Williams | Mar 26, 2026 at 2:32 PM EDT

VHT Lagged the Market by 57 Points Over 5 Years. Here Is Why Long-Term Investors Still Hold It

Healthcare spending doesn’t stop during recessions. That structural reality is the core argument for owning Vanguard Health Care ETF (NYSEARCA:VHT),…

Joel South | Mar 17, 2026 at 11:56 AM EDT

Why One Analyst Thinks Johnson & Johnson Reaches $280

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) has been one of healthcare’s standout performers over the past year, with…

Tony Dong | Mar 9, 2026 at 9:33 AM EDT

The “Cockroach” Portfolio: Why This 5-ETF Strategy Is Every Retiree’s Best Defense Against a 2026 Recession

Talk of a recession is once again dominating the headlines. The latest job report has just been released, showing a…

Austin Smith | Feb 18, 2026 at 5:32 AM EST

XLV is A $41 Billion Defensive Healthcare Play That Looks Good Until You Compare To The S&P 500

Healthcare isn’t going anywhere. An aging population, chronic disease management, and breakthrough treatments ensure this sector remains essential regardless of…

Joey Frenette | Jan 29, 2026 at 12:16 PM EST

2 Hot Sector ETFs Worth Buying in 2026

Index investors and so-called Bogleheads (those who love the Vanguard ETFs) may not be all too fond of the sector…

Michael Williams | Jan 29, 2026 at 8:20 AM EST

PINK’s 58% Gains Since 2021 Come From Picking Winners, Not Owning Everything

Healthcare is supposed to be defensive. When tech stocks swing wildly and consumer spending wobbles, healthcare companies keep selling drugs,…

1 2

Health Care Select Sector SPDR Fund : XLV

XLV

$159.49

All XLV Articles

Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%

Goldman’s Top Strategist Sees a Dangerous Amount of Leverage Piling Up

The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026

3 Ridiculously Cheap Healthcare Stocks to Buy in June

Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech

Humana Jumps 6%, UnitedHealth Climbs 5%, Cigna Rises 4% as Analysts Cheer Softer Medical Cost Trends

When 2022 Tore Through the S&P 500, This Healthcare ETF Barely Flinched. Why Isn’t It in More Retirement Accounts?

Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

Healthcare’s Defensive Promise Crumbles: XLV Down 7% While SPY Rises 5% in 2026

VHT Lagged the Market by 57 Points Over 5 Years. Here Is Why Long-Term Investors Still Hold It

Why One Analyst Thinks Johnson & Johnson Reaches $280

The “Cockroach” Portfolio: Why This 5-ETF Strategy Is Every Retiree’s Best Defense Against a 2026 Recession

XLV is A $41 Billion Defensive Healthcare Play That Looks Good Until You Compare To The S&P 500

2 Hot Sector ETFs Worth Buying in 2026

PINK’s 58% Gains Since 2021 Come From Picking Winners, Not Owning Everything

Tom Lee’s ‘Granny Shots’ ETF Is Beating the S&P Again, and He’s Calling for 8,000

If You Just Inherited an IRA, Read This

Tesla Is Still Down 17% in 2026. Can Wednesday’s Earnings Event Get TSLA Stock Back on Track?

If You Just Inherited an IRA, Read This

She's a 62-Year-Old Widow Banking on the COLA Raise. The Survivor-Benefit Timing She's Ignoring Is Worth Far More.

NLR Trades at 0.61%: Why This Nuclear Fund Beats Uranium Miners

Tom Lee’s ‘Granny Shots’ ETF Is Beating the S&P Again, and He’s Calling for 8,000

Health Care Select Sector SPDR Fund : XLV

XLV

$159.49

All XLV Articles

Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%

Goldman’s Top Strategist Sees a Dangerous Amount of Leverage Piling Up

The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026

3 Ridiculously Cheap Healthcare Stocks to Buy in June

Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech

Humana Jumps 6%, UnitedHealth Climbs 5%, Cigna Rises 4% as Analysts Cheer Softer Medical Cost Trends

When 2022 Tore Through the S&P 500, This Healthcare ETF Barely Flinched. Why Isn’t It in More Retirement Accounts?

Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

Healthcare’s Defensive Promise Crumbles: XLV Down 7% While SPY Rises 5% in 2026

VHT Lagged the Market by 57 Points Over 5 Years. Here Is Why Long-Term Investors Still Hold It

Why One Analyst Thinks Johnson & Johnson Reaches $280

The “Cockroach” Portfolio: Why This 5-ETF Strategy Is Every Retiree’s Best Defense Against a 2026 Recession

XLV is A $41 Billion Defensive Healthcare Play That Looks Good Until You Compare To The S&P 500

2 Hot Sector ETFs Worth Buying in 2026

PINK’s 58% Gains Since 2021 Come From Picking Winners, Not Owning Everything

Tom Lee’s ‘Granny Shots’ ETF Is Beating the S&P Again, and He’s Calling for 8,000

If You Just Inherited an IRA, Read This

Tesla Is Still Down 17% in 2026. Can Wednesday’s Earnings Event Get TSLA Stock Back on Track?

Featured Reads

If You Just Inherited an IRA, Read This

She's a 62-Year-Old Widow Banking on the COLA Raise. The Survivor-Benefit Timing She's Ignoring Is Worth Far More.